| Published Application/Species/Sample/Dilution | Reference |
|---|
- flow cytometry; human; fig 1
| Deisting W, Raum T, Kufer P, Baeuerle P, Münz M. Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110. PLoS ONE. 2015;10:e0141669 pubmed publisher |
- flow cytometry; human; fig s4
| James S, Fox J, Afsari F, Lee J, Clough S, Knight C, et al. Multiparameter Analysis of Human Bone Marrow Stromal Cells Identifies Distinct Immunomodulatory and Differentiation-Competent Subtypes. Stem Cell Reports. 2015;4:1004-15 pubmed publisher |
| Yan L, Sun Y, Guo J, Jia R. PD-L1 Exon 3 Is a Hidden Switch of Its Expression and Function in Oral Cancer Cells. Int J Mol Sci. 2023;24: pubmed publisher |
| Falc xf3 n Cama V, Montero Gonz xe1 lez T, Acosta Medina E, Guillen Nieto G, Berlanga Acosta J, Fern xe1 ndez Ortega C, et al. Evidence of SARS-CoV-2 infection in postmortem lung, kidney, and liver samples, revealing cellular targets involved in COVID-19 pathogenesis. Arch Virol. 2023;168:96 pubmed publisher |
| Liu Y, Xu Q, Deng F, Zheng Z, Luo J, Wang P, et al. HERC2 promotes inflammation-driven cancer stemness and immune evasion in hepatocellular carcinoma by activating STAT3 pathway. J Exp Clin Cancer Res. 2023;42:38 pubmed publisher |
| Coelho M, Cooper S, Strauss M, Karakoc E, Bhosle S, Gon xe7 alves E, et al. Base editing screens map mutations affecting interferon-γ signaling in cancer. Cancer Cell. 2023;41:288-303.e6 pubmed publisher |
| Lam W, Hu R, Liu S, Cheng P, Cheng Y. YIV-906 enhances nuclear factor of activated T-cells (NFAT) activity of T cells and promotes immune checkpoint blockade antibody action and CAR T-cell activity. Front Pharmacol. 2022;13:1095186 pubmed publisher |
| Turiello R, Capone M, Morretta E, Monti M, Madonna G, Azzaro R, et al. Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents. J Immunother Cancer. 2022;10: pubmed publisher |
| van Duijn A, Willemsen K, van Uden N, Hoyng L, Erades S, Koster J, et al. A secondary role for hypoxia and HIF1 in the regulation of (IFNγ-induced) PD-L1 expression in melanoma. Cancer Immunol Immunother. 2022;71:529-540 pubmed publisher |
| Klopotowska M, Bajor M, Graczyk Jarzynka A, Kraft A, Pilch Z, Zhylko A, et al. PRDX-1 Supports the Survival and Antitumor Activity of Primary and CAR-Modified NK Cells under Oxidative Stress. Cancer Immunol Res. 2021;: pubmed publisher |
| O Connor R, Chauhan V, Mathieson L, Titmarsh H, Koppensteiner L, Young I, et al. T cells drive negative feedback mechanisms in cancer associated fibroblasts, promoting expression of co-inhibitory ligands, CD73 and IL-27 in non-small cell lung cancer. Oncoimmunology. 2021;10:1940675 pubmed publisher |
| YEKU O, Rao T, Laster I, Kononenko A, Purdon T, Wang P, et al. Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition. Front Immunol. 2021;12:663379 pubmed publisher |
| Xu S, Wang X, Yang Y, Li Y, Wu S. LSD1 silencing contributes to enhanced efficacy of anti-CD47/PD-L1 immunotherapy in cervical cancer. Cell Death Dis. 2021;12:282 pubmed publisher |
| Wang D, Prager B, Gimple R, Aguilar B, Alizadeh D, Tang H, et al. CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based Therapies. Cancer Discov. 2021;11:1192-1211 pubmed publisher |
| Li Z, Li B, Li L, Wang G, Li Y, Fu R, et al. The Immunostimulative Effect and Mechanisms of a Novel Mouse Anti-Human PD-1 Monoclonal Antibody on Jurkat Lymphocytic Cells Cocultured with Hepatoma Cells. Onco Targets Ther. 2020;13:12225-12241 pubmed publisher |
| Boschert V, Teusch J, Aljasem A, Schmucker P, Klenk N, Straub A, et al. HGF-Induced PD-L1 Expression in Head and Neck Cancer: Preclinical and Clinical Findings. Int J Mol Sci. 2020;21: pubmed publisher |
| Moorlag S, Rodriguez Rosales Y, Gillard J, Fanucchi S, Theunissen K, Novakovic B, et al. BCG Vaccination Induces Long-Term Functional Reprogramming of Human Neutrophils. Cell Rep. 2020;33:108387 pubmed publisher |
| Giamarellos Bourboulis E, Tsilika M, Moorlag S, Antonakos N, Kotsaki A, Domínguez Andrés J, et al. Activate: Randomized Clinical Trial of BCG Vaccination against Infection in the Elderly. Cell. 2020;183:315-323.e9 pubmed publisher |
| Suwandi J, Laban S, Vass K, Joosten A, van Unen V, Lelieveldt B, et al. Multidimensional analyses of proinsulin peptide-specific regulatory T cells induced by tolerogenic dendritic cells. J Autoimmun. 2020;107:102361 pubmed publisher |
| Kong T, Ahn R, Yang K, Zhu X, Fu Z, Morin G, et al. CD44 Promotes PD-L1 Expression and Its Tumor-Intrinsic Function in Breast and Lung Cancers. Cancer Res. 2020;80:444-457 pubmed publisher |
| Musielak B, Kocik J, Skalniak L, Magiera Mularz K, Sala D, Czub M, et al. CA-170 - A Potent Small-Molecule PD-L1 Inhibitor or Not?. Molecules. 2019;24: pubmed publisher |
| Pan Y, Fei Q, Xiong P, Yang J, Zhang Z, Lin X, et al. Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1. Oncoimmunology. 2019;8:e1581529 pubmed publisher |
| Guo X, Jiang H, Shi B, Zhou M, Zhang H, Shi Z, et al. Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma. Front Pharmacol. 2018;9:1118 pubmed publisher |
| Dijkstra K, Cattaneo C, Weeber F, Chalabi M, van de Haar J, Fanchi L, et al. Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids. Cell. 2018;174:1586-1598.e12 pubmed publisher |
| Zhao Y, Harrison D, Song Y, Ji J, Huang J, Hui E. Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells. Cell Rep. 2018;24:379-390.e6 pubmed publisher |
| Martin A, Nirschl C, Polanczyk M, Bell W, Nirschl T, Harris Bookman S, et al. PD-L1 expression in medulloblastoma: an evaluation by subgroup. Oncotarget. 2018;9:19177-19191 pubmed publisher |
| Narasimhan P, Akabas L, Tariq S, Huda N, Bennuru S, Sabzevari H, et al. Similarities and differences between helminth parasites and cancer cell lines in shaping human monocytes: Insights into parallel mechanisms of immune evasion. PLoS Negl Trop Dis. 2018;12:e0006404 pubmed publisher |
| Sun C, Lan P, Han Q, Huang M, Zhang Z, Xu G, et al. Oncofetal gene SALL4 reactivation by hepatitis B virus counteracts miR-200c in PD-L1-induced T cell exhaustion. Nat Commun. 2018;9:1241 pubmed publisher |
| Zheng B, Ren T, Huang Y, Sun K, Wang S, Bao X, et al. PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse. J Hematol Oncol. 2018;11:16 pubmed publisher |
| Witt D, Donson A, Amani V, Moreira D, Sanford B, Hoffman L, et al. Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy. Pediatr Blood Cancer. 2018;65:e26960 pubmed publisher |
| Coelho M, de Carné Trécesson S, Rana S, Zecchin D, Moore C, Molina Arcas M, et al. Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA. Immunity. 2017;47:1083-1099.e6 pubmed publisher |
| Cao J, Brouwer N, Richards K, Marinkovic M, van Duinen S, Hurkmans D, et al. PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma. Oncotarget. 2017;8:54722-54734 pubmed publisher |
| Layer J, Kronmüller M, Quast T, van den Boorn Konijnenberg D, Effern M, Hinze D, et al. Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression. Oncoimmunology. 2017;6:e1320626 pubmed publisher |
| Jiang H, Rivera Molina Y, Gomez Manzano C, Clise Dwyer K, Bover L, Vence L, et al. Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination. Cancer Res. 2017;77:3894-3907 pubmed publisher |
| Lin A, Twitty C, Burnett R, Hofacre A, Mitchell L, Espinoza F, et al. Retroviral Replicating Vector Delivery of miR-PDL1 Inhibits Immune Checkpoint PDL1 and Enhances Immune Responses In Vitro. Mol Ther Nucleic Acids. 2017;6:221-232 pubmed publisher |
| Davies L, Heldring N, Kadri N, Le Blanc K. Mesenchymal Stromal Cell Secretion of Programmed Death-1 Ligands Regulates T Cell Mediated Immunosuppression. Stem Cells. 2017;35:766-776 pubmed publisher |
| Brodska B, Otevrelova P, Kuzelova K. Correlation of PD-L1 Surface Expression on Leukemia Cells with the Ratio of PD-L1 mRNA Variants and with Electrophoretic Mobility. Cancer Immunol Res. 2016;4:815-819 pubmed |
| Cherkassky L, Morello A, Villena Vargas J, Feng Y, Dimitrov D, Jones D, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016;126:3130-44 pubmed publisher |
| Tang Z, Hao Y, Zhang E, Xu C, Zhou Y, Zheng X, et al. CD28 family of receptors on T cells in chronic HBV infection: Expression characteristics, clinical significance and correlations with PD-1 blockade. Mol Med Rep. 2016;14:1107-16 pubmed publisher |
| Zhang J, Wang C, Zhang P, Wang X, Chen J, Yang J, et al. Expression of programmed death 1 ligand 1 on periodontal tissue cells as a possible protective feedback mechanism against periodontal tissue destruction. Mol Med Rep. 2016;13:2423-30 pubmed publisher |
| Carbotti G, Barisione G, Airoldi I, Mezzanzanica D, Bagnoli M, Ferrero S, et al. IL-27 induces the expression of IDO and PD-L1 in human cancer cells. Oncotarget. 2015;6:43267-80 pubmed publisher |
| Sponaas A, Moharrami N, Feyzi E, Standal T, Holth Rustad E, Waage A, et al. PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy. PLoS ONE. 2015;10:e0139867 pubmed publisher |
| Wang W, Yen M, Liu K, Hsu P, Lin M, Chen P, et al. Interleukin-25 Mediates Transcriptional Control of PD-L1 via STAT3 in Multipotent Human Mesenchymal Stromal Cells (hMSCs) to Suppress Th17 Responses. Stem Cell Reports. 2015;5:392-404 pubmed publisher |
| Martin A, Nirschl T, Nirschl C, Francica B, Kochel C, Van Bokhoven A, et al. Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance. Prostate Cancer Prostatic Dis. 2015;18:325-32 pubmed publisher |
| Sommer A, Fabri M. Vitamin D regulates cytokine patterns secreted by dendritic cells to promote differentiation of IL-22-producing T cells. PLoS ONE. 2015;10:e0130395 pubmed publisher |
| Heeren A, Koster B, Samuels S, Ferns D, Chondronasiou D, Kenter G, et al. High and interrelated rates of PD-L1+CD14+ antigen-presenting cells and regulatory T cells mark the microenvironment of metastatic lymph nodes from patients with cervical cancer. Cancer Immunol Res. 2015;3:48-58 pubmed publisher |
| Planès R, BenMohamed L, Leghmari K, Delobel P, Izopet J, Bahraoui E. HIV-1 Tat protein induces PD-L1 (B7-H1) expression on dendritic cells through tumor necrosis factor alpha- and toll-like receptor 4-mediated mechanisms. J Virol. 2014;88:6672-89 pubmed publisher |
| Pen J, Keersmaecker B, Heirman C, Corthals J, Liechtenstein T, Escors D, et al. Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells. Gene Ther. 2014;21:262-71 pubmed publisher |
| Legat A, Speiser D, Pircher H, Zehn D, Fuertes Marraco S. Inhibitory Receptor Expression Depends More Dominantly on Differentiation and Activation than "Exhaustion" of Human CD8?T Cells. Front Immunol. 2013;4:455 pubmed publisher |
| Baglio F, Saresella M, Preti M, Cabinio M, Griffanti L, Marventano I, et al. Neuroinflammation and brain functional disconnection in Alzheimer's disease. Front Aging Neurosci. 2013;5:81 pubmed publisher |
| Maine C, Aziz N, Chatterjee J, Hayford C, Brewig N, Whilding L, et al. Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer. Cancer Immunol Immunother. 2014;63:215-24 pubmed publisher |
| Seliger B. B7-H abnormalities in melanoma and clinical relevance. Methods Mol Biol. 2014;1102:367-80 pubmed publisher |
| Luheshi N, Davies G, Poon E, Wiggins K, McCourt M, Legg J. Th1 cytokines are more effective than Th2 cytokines at licensing anti-tumour functions in CD40-activated human macrophages in vitro. Eur J Immunol. 2014;44:162-72 pubmed publisher |
| Haile S, Dalal S, Clements V, Tamada K, Ostrand Rosenberg S. Soluble CD80 restores T cell activation and overcomes tumor cell programmed death ligand 1-mediated immune suppression. J Immunol. 2013;191:2829-36 pubmed publisher |
| Singh A, Mohan A, Dey A, Mitra D. Inhibiting the programmed death 1 pathway rescues Mycobacterium tuberculosis-specific interferon ?-producing T cells from apoptosis in patients with pulmonary tuberculosis. J Infect Dis. 2013;208:603-15 pubmed publisher |
| Bloch O, Crane C, Kaur R, Safaee M, Rutkowski M, Parsa A. Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin Cancer Res. 2013;19:3165-75 pubmed publisher |
| Méndez Reguera A, Pérez Montesinos G, Alcántara Hernández M, Martínez Estrada V, Cazarin Barrientos J, Rojas Espinosa O, et al. Pathogenic CCR6+ dendritic cells in the skin lesions of discoid lupus patients: a role for damage-associated molecular patterns. Eur J Dermatol. 2013;23:169-82 pubmed publisher |
| Huang G, Wen Q, Zhao Y, Gao Q, Bai Y. NF-?B plays a key role in inducing CD274 expression in human monocytes after lipopolysaccharide treatment. PLoS ONE. 2013;8:e61602 pubmed publisher |
| Knol A, Nguyen J, Pandolfino M, Quereux G, Brocard A, Peuvrel L, et al. Tissue biomarkers in melanoma patients treated with TIL. PLoS ONE. 2012;7:e48729 pubmed publisher |
| Singh A, Dey A, Mohan A, Sharma P, Mitra D. Foxp3+ regulatory T cells among tuberculosis patients: impact on prognosis and restoration of antigen specific IFN-? producing T cells. PLoS ONE. 2012;7:e44728 pubmed publisher |
| Severa M, Giacomini E, Gafa V, Anastasiadou E, Rizzo F, Corazzari M, et al. EBV stimulates TLR- and autophagy-dependent pathways and impairs maturation in plasmacytoid dendritic cells: implications for viral immune escape. Eur J Immunol. 2013;43:147-58 pubmed publisher |
| Lichtenegger F, Mueller K, Otte B, Beck B, Hiddemann W, Schendel D, et al. CD86 and IL-12p70 are key players for T helper 1 polarization and natural killer cell activation by Toll-like receptor-induced dendritic cells. PLoS ONE. 2012;7:e44266 pubmed publisher |
| Ou J, Wiedeman A, Stevens A. TNF-? and TGF-? counter-regulate PD-L1 expression on monocytes in systemic lupus erythematosus. Sci Rep. 2012;2:295 pubmed publisher |
| Ioannou M, Alissafi T, Lazaridis I, Deraos G, Matsoukas J, Gravanis A, et al. Crucial role of granulocytic myeloid-derived suppressor cells in the regulation of central nervous system autoimmune disease. J Immunol. 2012;188:1136-46 pubmed publisher |
| Fujimura T, Ring S, Umansky V, Mahnke K, Enk A. Regulatory T cells stimulate B7-H1 expression in myeloid-derived suppressor cells in ret melanomas. J Invest Dermatol. 2012;132:1239-46 pubmed publisher |
| Wang B, Bao J, Wang J, Wang Y, Jiang M, Xing M, et al. Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma. World J Gastroenterol. 2011;17:3322-9 pubmed publisher |
| Zheng J, Umikawa M, Zhang S, Huynh H, Silvany R, Chen B, et al. Ex vivo expanded hematopoietic stem cells overcome the MHC barrier in allogeneic transplantation. Cell Stem Cell. 2011;9:119-30 pubmed publisher |
| Kim Y, Park S, Broxmeyer H. Phagocytosis, a potential mechanism for myeloid-derived suppressor cell regulation of CD8+ T cell function mediated through programmed cell death-1 and programmed cell death-1 ligand interaction. J Immunol. 2011;187:2291-301 pubmed publisher |
| Morbach H, Wiegering V, Richl P, Schwarz T, Suffa N, Eichhorn E, et al. Activated memory B cells may function as antigen-presenting cells in the joints of children with juvenile idiopathic arthritis. Arthritis Rheum. 2011;63:3458-66 pubmed publisher |
| Figel A, Brech D, Prinz P, Lettenmeyer U, Eckl J, Turqueti Neves A, et al. Human renal cell carcinoma induces a dendritic cell subset that uses T-cell crosstalk for tumor-permissive milieu alterations. Am J Pathol. 2011;179:436-51 pubmed publisher |
| Zhao Q, Xiao X, Wu Y, Wei Y, Zhu L, Zhou J, et al. Interleukin-17-educated monocytes suppress cytotoxic T-cell function through B7-H1 in hepatocellular carcinoma patients. Eur J Immunol. 2011;41:2314-22 pubmed publisher |
| Haile S, Bosch J, Agu N, Zeender A, Somasundaram P, Srivastava M, et al. Tumor cell programmed death ligand 1-mediated T cell suppression is overcome by coexpression of CD80. J Immunol. 2011;186:6822-9 pubmed publisher |
| Andorsky D, Yamada R, Said J, Pinkus G, Betting D, Timmerman J. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res. 2011;17:4232-44 pubmed publisher |
| Saresella M, Calabrese E, Marventano I, Piancone F, Gatti A, Farina E, et al. A potential role for the PD1/PD-L1 pathway in the neuroinflammation of Alzheimer's disease. Neurobiol Aging. 2012;33:624.e11-22 pubmed publisher |
| Frigola X, Inman B, Lohse C, Krco C, Cheville J, Thompson R, et al. Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clin Cancer Res. 2011;17:1915-23 pubmed publisher |
| Zhang Y, Li J, Lou J, Zhou Y, Bo L, Zhu J, et al. Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients. Crit Care. 2011;15:R70 pubmed publisher |
| Banerjee S, Lin C, Skinner K, Schiffhauer L, Peacock J, Hicks D, et al. Heat shock protein 27 differentiates tolerogenic macrophages that may support human breast cancer progression. Cancer Res. 2011;71:318-27 pubmed publisher |
| van de Laar L, van den Bosch A, van der Kooij S, Janssen H, Coffer P, van Kooten C, et al. A nonredundant role for canonical NF-?B in human myeloid dendritic cell development and function. J Immunol. 2010;185:7252-61 pubmed publisher |
| Deshpande M, Tipnis S, Shetty P, Ghosh D, Viswanathan C, Majumdar A. Immunologic properties of human dermal fibroblasts. Hum Immunol. 2010;71:1089-98 pubmed publisher |
| Hsu M, Hsiao J, Chang K, Wu Y, Su I, Jin Y, et al. Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma. Mod Pathol. 2010;23:1393-403 pubmed publisher |
| Wu Y, Lin C, Cheng K, Lin C, Wang Y, Lin I, et al. Increased programmed death-ligand-1 expression in human gastric epithelial cells in Helicobacter pylori infection. Clin Exp Immunol. 2010;161:551-9 pubmed publisher |
| Alvarez I, Pasquinelli V, Jurado J, Abbate E, Musella R, de la Barrera S, et al. Role played by the programmed death-1-programmed death ligand pathway during innate immunity against Mycobacterium tuberculosis. J Infect Dis. 2010;202:524-32 pubmed publisher |
| Plege A, Borns K, Beer L, Baars W, Klempnauer J, Schwinzer R. Downregulation of cytolytic activity of human effector cells by transgenic expression of human PD-ligand-1 on porcine target cells. Transpl Int. 2010;23:1293-300 pubmed publisher |
| Kleijwegt F, Laban S, Duinkerken G, Joosten A, Zaldumbide A, Nikolic T, et al. Critical role for TNF in the induction of human antigen-specific regulatory T cells by tolerogenic dendritic cells. J Immunol. 2010;185:1412-8 pubmed publisher |
| Raptopoulou A, Bertsias G, Makrygiannakis D, Verginis P, Kritikos I, Tzardi M, et al. The programmed death 1/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis. Arthritis Rheum. 2010;62:1870-80 pubmed publisher |
| Benson D, Bakan C, Mishra A, Hofmeister C, Efebera Y, Becknell B, et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood. 2010;116:2286-94 pubmed publisher |
| Cavaleiro R, Baptista A, Soares R, Tendeiro R, Foxall R, Gomes P, et al. Major depletion of plasmacytoid dendritic cells in HIV-2 infection, an attenuated form of HIV disease. PLoS Pathog. 2009;5:e1000667 pubmed publisher |
| Zhang L, Bertucci A, Ramsey Goldman R, Burt R, Datta S. Regulatory T cell (Treg) subsets return in patients with refractory lupus following stem cell transplantation, and TGF-beta-producing CD8+ Treg cells are associated with immunological remission of lupus. J Immunol. 2009;183:6346-58 pubmed publisher |
| Kvistborg P, Boegh M, Pedersen A, Claesson M, Zocca M. Fast generation of dendritic cells. Cell Immunol. 2009;260:56-62 pubmed publisher |
| Xie Z, Chen Y, Zhao S, Yang Z, Yao X, Guo S, et al. Intrahepatic PD-1/PD-L1 up-regulation closely correlates with inflammation and virus replication in patients with chronic HBV infection. Immunol Invest. 2009;38:624-38 pubmed |
| Trabattoni D, Saresella M, Pacei M, Marventano I, Mendozzi L, Rovaris M, et al. Costimulatory pathways in multiple sclerosis: distinctive expression of PD-1 and PD-L1 in patients with different patterns of disease. J Immunol. 2009;183:4984-93 pubmed publisher |
| Pedersen A, Holmstrøm K, Jensen S, Fuchs D, Rasmussen S, Kvistborg P, et al. Phenotypic and functional markers for 1alpha,25-dihydroxyvitamin D(3)-modified regulatory dendritic cells. Clin Exp Immunol. 2009;157:48-59 pubmed publisher |
| Wilcox R, Feldman A, Wada D, Yang Z, Comfere N, Dong H, et al. B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood. 2009;114:2149-58 pubmed publisher |
| Zhang Z, Jin B, Zhang J, Xu B, Wang H, Shi M, et al. Dynamic decrease in PD-1 expression correlates with HBV-specific memory CD8 T-cell development in acute self-limited hepatitis B patients. J Hepatol. 2009;50:1163-73 pubmed publisher |
| Gehring A, Ho Z, Tan A, Aung M, Lee K, Tan K, et al. Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma. Gastroenterology. 2009;137:682-90 pubmed publisher |
| Fourcade J, Kudela P, Sun Z, Shen H, Land S, Lenzner D, et al. PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol. 2009;182:5240-9 pubmed publisher |
| Yao Y, Tao R, Wang X, Wang Y, Mao Y, Zhou L. B7-H1 is correlated with malignancy-grade gliomas but is not expressed exclusively on tumor stem-like cells. Neuro Oncol. 2009;11:757-66 pubmed publisher |
| Gong A, Zhou R, Hu G, Li X, Splinter P, O Hara S, et al. MicroRNA-513 regulates B7-H1 translation and is involved in IFN-gamma-induced B7-H1 expression in cholangiocytes. J Immunol. 2009;182:1325-33 pubmed |
| Bertsias G, Nakou M, Choulaki C, Raptopoulou A, Papadimitraki E, Goulielmos G, et al. Genetic, immunologic, and immunohistochemical analysis of the programmed death 1/programmed death ligand 1 pathway in human systemic lupus erythematosus. Arthritis Rheum. 2009;60:207-18 pubmed publisher |
| Liang M, Yang H, Fu J. Nimesulide inhibits IFN-gamma-induced programmed death-1-ligand 1 surface expression in breast cancer cells by COX-2 and PGE2 independent mechanisms. Cancer Lett. 2009;276:47-52 pubmed publisher |
| Kinter A, Godbout E, McNally J, Sereti I, Roby G, O Shea M, et al. The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol. 2008;181:6738-46 pubmed |
| Wang X, Zhang Z, Zhang S, Fu J, Yao J, Jiao Y, et al. B7-H1 up-regulation impairs myeloid DC and correlates with disease progression in chronic HIV-1 infection. Eur J Immunol. 2008;38:3226-36 pubmed publisher |
| Zhang J, Zhang Z, Jin B, Zhang S, Zhou C, Fu J, et al. Cutting edge: programmed death-1 up-regulation is involved in the attrition of cytomegalovirus-specific CD8+ T cells in acute self-limited hepatitis B virus infection. J Immunol. 2008;181:3741-4 pubmed |
| Butte M, Pena Cruz V, Kim M, Freeman G, Sharpe A. Interaction of human PD-L1 and B7-1. Mol Immunol. 2008;45:3567-72 pubmed publisher |
| Jaehn P, Zaenker K, Schmitz J, Dzionek A. Functional dichotomy of plasmacytoid dendritic cells: antigen-specific activation of T cells versus production of type I interferon. Eur J Immunol. 2008;38:1822-32 pubmed publisher |
| Taglauer E, Trikhacheva A, Slusser J, Petroff M. Expression and function of PDCD1 at the human maternal-fetal interface. Biol Reprod. 2008;79:562-9 pubmed publisher |
| Lafon M, Mégret F, Meuth S, Simon O, Velandia Romero M, Lafage M, et al. Detrimental contribution of the immuno-inhibitor B7-H1 to rabies virus encephalitis. J Immunol. 2008;180:7506-15 pubmed |
| Yang W, Chen P, Li H, Alizadeh H, Niederkorn J. PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro. Invest Ophthalmol Vis Sci. 2008;49:2518-25 pubmed publisher |
| Ghebeh H, Barhoush E, Tulbah A, Elkum N, Al Tweigeri T, Dermime S. FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer. 2008;8:57 pubmed publisher |
| Onlamoon N, Rogers K, Mayne A, Pattanapanyasat K, Mori K, Villinger F, et al. Soluble PD-1 rescues the proliferative response of simian immunodeficiency virus-specific CD4 and CD8 T cells during chronic infection. Immunology. 2008;124:277-93 pubmed publisher |
| Gröschel S, Piggott K, Vaglio A, Ma Krupa W, Singh K, Goronzy J, et al. TLR-mediated induction of negative regulatory ligands on dendritic cells. J Mol Med (Berl). 2008;86:443-55 pubmed publisher |
| Waggoner S, Hall C, Hahn Y. HCV core protein interaction with gC1q receptor inhibits Th1 differentiation of CD4+ T cells via suppression of dendritic cell IL-12 production. J Leukoc Biol. 2007;82:1407-19 pubmed |
| Ghebeh H, Tulbah A, Mohammed S, Elkum N, Bin Amer S, Al Tweigeri T, et al. Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells. Int J Cancer. 2007;121:751-8 pubmed |
| Perrot I, Blanchard D, Freymond N, Isaac S, Guibert B, Pacheco Y, et al. Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. J Immunol. 2007;178:2763-9 pubmed |
| Ghebeh H, Mohammed S, Al Omair A, Qattan A, Lehe C, Al Qudaihi G, et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia. 2006;8:190-8 pubmed |
| Chen Y, Zhang J, Li J, Zou L, Zhao T, Tang Y, et al. Expression of B7-H1 in inflammatory renal tubular epithelial cells. Nephron Exp Nephrol. 2006;102:e81-92 pubmed |
| Methe H, Nugent H, Groothuis A, Seifert P, Sayegh M, Edelman E. Matrix embedding alters the immune response against endothelial cells in vitro and in vivo. Circulation. 2005;112:I89-95 pubmed |
| Azam P, Peiffer J, Chamousset D, Tissier M, Bonnet P, Vian L, et al. The cytokine-dependent MUTZ-3 cell line as an in vitro model for the screening of contact sensitizers. Toxicol Appl Pharmacol. 2006;212:14-23 pubmed |
| Wilmotte R, Burkhardt K, Kindler V, Belkouch M, Dussex G, Tribolet N, et al. B7-homolog 1 expression by human glioma: a new mechanism of immune evasion. Neuroreport. 2005;16:1081-5 pubmed |
| Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N, et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res. 2005;11:2947-53 pubmed |
